Kelly Pietrzak
Adult Health · Cheektowaga, NYNPI 1063572378
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,500 of the $52,122 with a category attached, or 81.5%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 86.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2023 at $14,625 and has fallen 71.1% since, to $4,227 in 2025. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 457 payments — averaging $114.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$45K
- Boehringer Ingelheim$1K
- Novartis$1K
- Amgen$972
- Impulse Dynamics (USA) Inc.$813
- Recor Medical Inc$480
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$42,50082%
- Food & beverage$9,62218%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 95 | $44,849 |
| Boehringer Ingelheim | 48 | $1,097 |
| Novartis | 68 | $1,036 |
| Amgen | 65 | $972 |
| Impulse Dynamics (USA) Inc. | 11 | $813 |
| Recor Medical Inc | 8 | $480 |
| Pfizer | 24 | $433 |
| Johnson & Johnson | 48 | $390 |
| E.r. Squibb & Sons, L.L.C. | 20 | $333 |
| Edwards Lifesciences | 4 | $317 |
| Abbott | 8 | $285 |
| Merck | 15 | $282 |
| Lexicon Pharmaceuticals, Inc. | 9 | $152 |
| Bayer | 4 | $75 |
| Itamar Medical Inc | 2 | $72 |
| Heartflow, Inc. | 3 | $66 |
| Abiomed | 3 | $59 |
| Scpharmaceuticals Inc. | 3 | $56 |
| Alnylam Pharmaceuticals Inc. | 3 | $56 |
| Boston Scientific | 2 | $47 |
| AstraZeneca | 3 | $45 |
| Novo Nordisk | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Cvrx, Inc. | 1 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,122 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 491 | $576,547 |
| EntrestoSacubitril/Valsartan | 210 | $285,405 |
| Repatha SureclickEvolocumab | 320 | $235,643 |
| JardianceEmpagliflozin | 165 | $208,522 |
| XareltoRivaroxaban | 114 | $140,678 |
| BrilintaTicagrelor | 63 | $57,307 |
| Repatha SyringeEvolocumab | 26 | $20,531 |
| FarxigaDapagliflozin Propanediol | 19 | $18,728 |
| MultaqDronedarone Hcl | 12 | $15,501 |
| Repatha PushtronexEvolocumab | 19 | $14,654 |
| Metoprolol Succinate | 572 | $11,523 |
| Praluent PenAlirocumab | 15 | $11,015 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $7,011 |
| Ranolazine ErRanolazine | 41 | $5,515 |
| Rosuvastatin Calcium | 280 | $4,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $433 | $576,547491 claims |
| NovartisEntresto | $1,036 | $285,405210 claims |
| Boehringer IngelheimJardiance | $1,097 | $208,522165 claims |
| Johnson & JohnsonXarelto | $390 | $140,678114 claims |
| AstraZenecaBrilinta, Farxiga | $45 | $76,03582 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in Cheektowaga
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Mary CiechoskiBuffalo$200K
- Jennifer FioriniGlens Falls$151K
- Katelyn McCormackAmherst$131K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
- Alyson HartyNew York$65K
- Danielle BrunoPlainview$61K
- Julie PlantamuraPort Jefferson Station$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.